Biotechnology is one of the best platforms to meet the demand for better healthcare infrastructure for the diagnosis and treatment of various infectious diseases and lower its sero-prevalence rate. It further promises treatment opportunities to some extremely fatal diseases such as cancer. As a result of this, various biotech companies are collaborating with similar organizations, and are majorly focusing on research and development activities to develop solutions through various novel techniques.
In the same way, two renowned organizations named C4U Corporation, (“C4U”) and Noile-Immune Biotech Inc., (“Noile-Immune”) have entered into an agreement to conduct joint research and to commercialize the next-generation allogeneic gene-modified immune cell therapy. This was reported on 27th June 2020 by Noile-Immune Biotech and C4U team.
The joint research will be done by combining C4U’s CRISPR/Cas3 genome editing technology along with the Noile-Immune’s PRIME (Proliferation inducing and migration enhancing) technology. This was primarily designed to improve the growth and transferring of immune cells into solid tumors.
Talking about CRISPR/Cas3, it is the core technology of C4U developed by its founders and advisors of Scientific Advisory Board of C4U. CRISPR/Cas3 technology can counteract the CRISPR/Cas9 system. CRISPR/Cas9, being presently the most studied technology all across the globe has further attracted substantial consideration as a favorable genome editing technology. Further, this technology is not disturbed by the complex patent status of Cas9.
PRIME technology, being the key technology of Noile-Immune, finds its correlation with the CAR-T and TCR-T cells which are majorly known as the genetically modified immune cell therapies. These are further considered as potent solution to fight against cancer and was developed by Dr. Koji Tamada, the scientific founder and director of Noile-Immune, professor of Yamaguchi University Graduate School of Medicine and Invited Professor at Center for gene and cell therapy, the Institute of Medical Science, the University of Tokyo.
PRIME technology successfully improves the gene-modified immune cells’ functions by producing cytokines and chemokines. Further, it also enhances the capacity of an individual’s immune system so as to cope with the cancer cells.
